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Reversing Neurodegeneration: Minireview
A Promise Unfolds
long before neuronal death becomes significant. Al-
though apoptosis plays a role in some neurological dis-
eases, data from both humans and animal models indi-
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Could this process be slowed if expression of a mutantHouston, Texas 77030
polyglutamine protein were suppressed after the dis-
ease process has begun? This is the question that Ya-
mamoto et al. address in their elegantly simple study.Few human ills have seemed as hopelessly intractable
They first established a line of mice carrying a transgeneas neurodegenerative diseases. Until recently, there has
with the tetO bidirectional promoter flanked by a lacZbeen little reason for optimism that we might halt the
reporter gene and exon 1 of huntingtin (htt) containingdegeneration, let alone cure it. But the work of ReneÂ
94 CAG repeats (HD94). They then crossed these miceHen and colleagues (Yamamoto et al., 2000), reported
with transgenics expressing the tetracycline-regulatedin this issue of Cell, shows that it is possible to arrest
transactivator (tTA) under the control of the calcium/neuronal degeneration, at least in early stages of the
calmodulin kinase IIa promoter, which have high expres-disease process. By creating a conditional mouse model
sion of the transgene in the forebrain (including the stria-of Huntington's disease (HD) that uses the tetracycline-
tum, a primary site of HD pathology). Expression of tTAresponsive gene systemÐand thus allows transgene
activates expression of both genes flanking the tetOexpression to be turned off by oral administration of
promoter. Thus, in double transgenic mice both trans-tetracyclineÐthey discovered that HD-like pathology is
genes are constitutively expressed. Doxycycline, a de-dependent on continuous expression of a fragment of
rivative of tetracycline that readily crosses the blood/huntingtin with an expanded polyglutamine tract.
brain barrier, abolishes expression from the tetO pro-Glutamine Repeat Diseases:
moter by binding to tTA and decreasing its affinity forProgressive Neurodegeneration
tetO. Interestingly, in order to obtain the expected yield
Huntington's disease is one of the more familiar mem-
of double transgenic offspring, pregnant females from
bers of a group of neurodegenerative disorders known
the heterozygote crosses had to be treated with doxycy-
as triplet repeat diseases. HD and the spinocerebellar
cline between gestation day E15 and birth. The explana-
ataxias (SCAs), among others, result from the expansion tion for this is somewhat unclear. Full-length mutant
of an unstable CAG trinucleotide repeat tract in the rele- huntingtin with an expanded polyglutamine tract res-
vant disease gene that causes an expanded stretch of cues the embryonic lethality caused by the absence of
glutamines in the resultant proteins (Kaytor and Warren, wild-type huntingtin (Hodgson et al., 1999). The embry-
1999). The polyglutamine tract itself seems to be the onic lethality seen in the double transgenic mice could
source of toxicity: transgenic mice expressing either reflect the greater toxicity expected of the truncated
intact protein with an expanded polyglutamine tract or huntingtin with an expanded polyglutamine tract, or it
a truncated protein containing the polyglutamine expan- could indicate ectopic and/or high expression of hun-
sion develop neurological phenotypes and neuropathol- tingtin due to the calcium/calmodulin kinase IIa pro-
ogy reminiscent of the human diseases (see Lin et al., moter.
1999 and references therein). Transgenic mice express- The double transgenic HD94 mice, in which the bidi-
ing protein with a normal polyglutamine tract (or null rectional transgene expression was activated by the
mice lacking the relevant protein function) do not de- removal of doxycycline at birth, revealed high levels of
velop the disease phenotype. Although the chief sites both HD94 and lacZ in the striatum, cortex, and hippo-
of neuropathology vary from one triplet repeat disease campus. A majority of striatal neurons displayed immu-
to the next, and the function of most of the proteins noreactivity to a huntingtin antibody, showing diffuse
remains unknown, this gain-of-function mechanism pre- nuclear staining as well as nuclear aggregates. By 8
dominates and all the diseases are progressive. The weeks of age, striatal morphological alterations in the
longer the repeat tract, the more severe the disease and HD94 mice included a reduced size, reactive gliosis,
the earlier its onset. In HD, as in most of the other triplet and a decrease in D1 receptors (a feature seen in HD
repeat diseases, the mutant proteins form nuclear ag- patients). All of the HD94 mice at this age also showed
gregates that have resisted the most strenuous bio- a behavioral abnormality common to mouse models of
chemical efforts to solubilize them. Even truncated pro- HD: when suspended by their tails, they clasp their
teins with an expanded polyglutamine tract form these limbs. This behavioral phenotype grew more severe over
time. By 20 weeks some of the HD94 mice also devel-aggregates; indeed, truncated proteins seem to be even
oped a mild tremor.more toxic than the full-length proteins. It is important
To ascertain whether disease progression requiredto note that symptoms arise from neuronal dysfunction
continuous expression of HD94, doxycycline was ad-
ministered to the double transgenic mice for 16 weeks,³ E-mail: harry@mail.ahc.umn.edu (H. T. O.), hzoghbi@bcm.tmc.edu
(H. Y. Z.). beginning at 18 weeks of age. LacZ staining showed
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Figure 1. A Model of Polyglutamine-Induced
Neurodegeneration and Its Reversal
(A) Expression of a mutant peptide with ex-
panded polyglutamine (Q) tract leads to neu-
ronal degeneration and eventual death. Note
that both aggregated and solitary protein in-
duce neuronal dysfunction that precedes
death.
(B) Turning off mutant protein expression
gives the neuron enough of a reprieve to clear
the mutant protein by the chaperone/ubiqui-
tin-proteasome pathway (UPP) and subse-
quently recover at least some function.
that the doxycycline regimen abolished expression of expanded polyglutamine tract could make the protein
resistant to degradation by altering its native structure;the transgene. After 16 weeks of treatment the polyglu-
tamine aggregates disappeared in the ªgene-offº mice, in vitro studies show that ataxin-1 with an expanded
polyglutamine tract is less efficiently degraded than itsand all the progressive striatal changes (decrease in
size, gliosis, and loss of D1 receptors) were arrested. wild-type counterpart, although both are ubiquitinated
equally well (Cummings et al., 1999). The colocalizationMore promising still, neurological function was partially
restored by the doxycycline treatment: the intensity of of various chaperones, ubiquitin, and components of
the proteasome with the aggregated proteins furtherclasping behavior decreased to a level comparable to
that seen in the double transgenics at 8 weeks of age, supports this model (Alves-Rodrigues et al., 1998; Lin
et al, 1999). Moving beyond the polyglutamine diseases,while the duration of clasping reversed to levels compa-
rable to those of control mice. a-synuclein with the A53T mutation is associated with
familial PD and has a 50% longer half-life than its wild-Does Impaired Protein Clearance
Cause Neurodegeneration? type counterpart (Bennett et al., 1999). Oligomerization
or fibril formation, promoted by the mutations in theAlzheimer's disease (AD), Parkinson's disease (PD),
amyotrophic lateral sclerosis (ALS), prion encephalopa- respective proteins, could also lead to protein accumu-
lation. Conway et al. (2000) demonstrated that the twothies, and the polyglutamine diseases are all character-
ized by the accumulation of protein either outside the disease-causing mutations in a-synuclein accelerate
the oligomerization of the protein. Whether the mutatedcell (e.g., amyloid plaques in AD) or within it (e.g., nuclear
inclusions in HD and cytoplasmic aggregates in PD and proteins gradually compromise the function of the pro-
teasome remains to be seen.ALS) (Kaytor and Warren, 1999). Although intracellular
aggregates are a common feature of polyglutamine dis- The importance of the ubiquitin±proteasome pathway
(UPP) in neuronal degeneration has been recently high-orders, they do not initiate disease. They seem instead
to manifest a neuron's efforts to cope with the mutant lighted (Kaytor and Warren, 1999; MacDonald, 1999).
Several neurodegenerative disorders are caused by mu-protein (Klement et al., 1998; Cummings et al., 1999). The
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tations in genes that play a role in the UPP. For example, than one disease, but it remains to be shown that this
a form of early-onset PD is caused by a missense muta- approach can be designed to avoid clearance of endog-
tion in the ubiquitin carboxy-terminal hydrolase L1 enous critical proteins. Factors that might enhance pro-
(UCH-L1) gene (Leroy et al., 1998). An in-frame intragenic tein clearance include components of the UPP and the
deletion in the mouse Uchl1 causes gracile axonal dys- chaperone pathway. Enhancing proteasomal activity,
trophy (gad), an autosomal recessive disorder charac- just like interfering with transcription, might have unde-
terized by sensory and motor ataxia, axonal degenera- sirable ramifications for some key neuronal proteins. If
tion, and ubiquitin-positive aggregates in the neurons specific proteasomal subunits play a role in substrate-
of the gracile nucleus (Saigoh et al., 1999). Uchl1 hydro- specific recognition, one is again faced with the need
lyzes bonds between degraded end products and ubi- to have a specific therapeutic approach for each of these
quitin to generate free monomeric ubiquitin; the deletion diseases. Should future research identify a unique struc-
removes 42 amino acids that contain a catalytic residue, tural property of proteins that undergo oligomerization
thus compromising the free ubiquitin pool necessary for and accumulation in these diseases, then perhaps a
an intact UPP. The SCA1 phenotype was recently found strategy that enhances the activity of a protease that
to be accelerated by loss of function of an E3 ligase selectively degrades such proteins would become an
(Ube3a) (Cummings et al., 1999). Finally, mutations in option. The discovery that overexpression of HSP40 or
Parkin, a member of the RING finger family of proteins, HSP70 modulates protein aggregation and/or cell death
cause an autosomal recessive juvenile form of PD (Ki- in cell culture models of SCA1, SCA3, and ALS (Cum-
tada et al., 1998). Several RING fingers interact with mings et al., 1998; Bruening et al., 1999; Chai et al., 1999)
ubiquitin-conjugating enzymes and mediate ubiquitina- and in Drosophila transgenic models of polyglutamine
tion (Lorick et al., 1999); the RING finger protein c-Cbl toxicity (Warrick et al., 1999) is exciting and suggests a
acts as an E3 ubiquitin ligase that recognizes target possible universal approach to this problem. Obviously,
substrates and promotes their ligation to ubiquitin the safety of chaperone overexpression needs to be
(Joazeiro et al., 1999). Although this connection remains determined, and the delivery of such chaperones to the
speculative, it reinforces the notion that mutations af- central nervous system is an open challenge.
fecting the UPP cause or worsen neurodegeneration. In sum, this is truly an exciting time for investigating
It thus appears that the pathogenesis of a large num- treatment avenues for late-onset neurodegenerative
ber of neurodegenerative diseases involves altered diseases. The cloning of human disease genes and the
ªprotein clearance.º Neuronal dysfunction could be study of mouse, fly, worm, and yeast models this past
caused by the mutant protein itself or its targets (as may decade provided tremendous insight into the pathogen-
be the case with UCHL1 and Parkin mutations), aberrant esis of neurodegenerative diseases. The discovery that
protein±protein interactions, alterations of gene expres- neurons are capable of at least some recovery has pro-
sion, or activation of an apoptotic pathway. The findings vided an exciting glimpse into the future use of a new
of Yamamoto et al. bring hope that if we can decrease generation of mouse models.
the load of mutant proteins, some of the neuronal dam-
age may be reversible. Selected Reading
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